Search: WFRF:(Párraga Alba Atienza)
> (2021) >
One Omics Approach ...
-
Kalushkova, AntoniaUppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab
(author)
One Omics Approach Does Not Rule Them All : The Metabolome and the Epigenome Join Forces in Haematological Malignancies
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-10-08
-
MDPI,2021
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-465076
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-465076URI
-
https://doi.org/10.3390/epigenomes5040022DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:234968247URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
De två första författarna delar förstaförfattarskapet.
-
Aberrant DNA methylation, dysregulation of chromatin-modifying enzymes, and microRNAs (miRNAs) play a crucial role in haematological malignancies. These epimutations, with an impact on chromatin accessibility and transcriptional output, are often associated with genomic instability and the emergence of drug resistance, disease progression, and poor survival. In order to exert their functions, epigenetic enzymes utilize cellular metabolites as co-factors and are highly dependent on their availability. By affecting the expression of metabolic enzymes, epigenetic modifiers may aid the generation of metabolite signatures that could be utilized as targets and biomarkers in cancer. This interdependency remains often neglected and poorly represented in studies, despite well-established methods to study the cellular metabolome. This review critically summarizes the current knowledge in the field to provide an integral picture of the interplay between epigenomic alterations and the cellular metabolome in haematological malignancies. Our recent findings defining a distinct metabolic signature upon response to enhancer of zeste homolog 2 (EZH2) inhibition in multiple myeloma (MM) highlight how a shift of preferred metabolic pathways may potentiate novel treatments. The suggested link between the epigenome and the metabolome in haematopoietic tumours holds promise for the use of metabolic signatures as possible biomarkers of response to treatment.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Nylund, PatrickUppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)patny852
(author)
-
Atienza Párraga, AlbaUppsala universitet,Experimentell och klinisk onkologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)albat684
(author)
-
Lennartsson, AndreasKarolinska Institutet
(author)
-
Jernberg Wiklund, HelenaUppsala universitet,Science for Life Laboratory, SciLifeLab,Experimentell och klinisk onkologi(Swepub:uu)helenajw
(author)
-
Uppsala universitetExperimentell och klinisk onkologi
(creator_code:org_t)
Related titles
-
In:EPIGENOMES: MDPI5:42075-4655
Internet link
Find in a library
-
EPIGENOMES
(Search for host publication in LIBRIS)
To the university's database